Skip to content

Pharmacokinetics and Dynamics of Nebulized Dexmedetomidine

Pharmacokinetics and Dynamics of Nebulized Dexmedetomidine in Preschool Children Undergoing Abdominal Cancer Surgery

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03762785
Enrollment
16
Registered
2018-12-04
Start date
2018-12-10
Completion date
2021-01-31
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Cancer

Keywords

pharmacokinitics, nebulized, dexmedetomidine, preschool children

Brief summary

the aim of this study is to study the pharmacokinetics and dynamics of nebulized dexmetedomidine in children undergoing major abdominal cancer surgery.

Detailed description

Inhalation of nebulized drug is an alternative route of administration that is relatively easy to set up, does not require venpuncture, but is associated with high bioavailability of the administered drug. Information on the pharmacokinetics of dexmedetomidine in the pediatric population is very limited, especially in children. To the best of investigators knowledge, there are no published reports on the pharmacokinetics of nebulized dexmedetomidine in children.

Interventions

inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* child aged 2-7 years * ASA I or II * scheduled for abdominal surgery * with average weight, height, normal serum albumin

Exclusion criteria

* patients with allergy to the study drug * patients with significant organ dysfunction * patients with cardiac arrhythmia * patients with congenital heart disease * use of psychotropic medication and mental retardation.

Design outcomes

Primary

MeasureTime frameDescription
pharmacokinitics of dexmedetomidineat the basline and after the end of nebuization of the drug at 5 minutes,15 minutes,30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutesserum level of dexmedetomidine

Secondary

MeasureTime frameDescription
sedation scorebaseline and after end of the drug adminstration by 30 mininuteRamsy sedation score 1 = Anxious or restless or both Unacceptable; increase sedation 2=Cooperative, orientated and tranquil Acceptable; no action necessary 3=Responding to commands Acceptable; no action necessary 4=Brisk response to stimulus Acceptable; no action necessary 5=Sluggish response to stimulus Unacceptable; monitor respiratory status and sedation level until stable at 2 or 3 6= No response to stimulus Unacceptable; monitor respiratory status and sedation level until stable at 2 or 3

Countries

Egypt

Contacts

Primary ContactShereen M Kamal, Lecturer
sheridouh79@yahoo.com+201006279209
Backup ContactHala S Abdelgafar, Profesor
hallasaad@yahoo.com+201003812011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026